Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491

Abstract

In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated with the presence of NAbs. The overriding evidence supports the view that the rate of NAb formation is low, does not differ significantly between the different type A BoNT products and that it is not the major factor in clinical response. BoNT products are highly effective and important therapies for the treatment of a variety of neurological and non-neurological conditions.

Keywords

• abobotulinumtoxin a
• botulinum neurotoxin (bont)
• immunogenicity
• incobotulinumtoxin a
• neutralising antibody (nab)
• onabotulinumtoxin a
• secondary non-responsiveness (snr)